Legal & General Group Plc Reduces Position in Progyny, Inc. (NASDAQ:PGNY)

Legal & General Group Plc trimmed its holdings in Progyny, Inc. (NASDAQ:PGNY) by 7.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 214,552 shares of the company’s stock after selling 16,158 shares during the period. Legal & General Group Plc owned 0.25% of Progyny worth $3,701,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC lifted its stake in Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company’s stock worth $11,835,000 after purchasing an additional 594,140 shares in the last quarter. Tidal Investments LLC lifted its position in Progyny by 67.7% during the third quarter. Tidal Investments LLC now owns 60,722 shares of the company’s stock worth $1,018,000 after buying an additional 24,507 shares in the last quarter. Franklin Resources Inc. boosted its stake in Progyny by 17.0% during the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company’s stock worth $759,000 after buying an additional 7,003 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in shares of Progyny by 89.8% during the 4th quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company’s stock worth $229,000 after acquiring an additional 6,270 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Price Performance

Shares of Progyny stock opened at $21.87 on Wednesday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.71, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The business has a 50-day moving average of $21.93 and a 200 day moving average of $18.94. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $33.84.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PGNY. Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Canaccord Genuity Group raised their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. JPMorgan Chase & Co. upped their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Progyny presently has a consensus rating of “Hold” and a consensus price target of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.